Innovation at scale: Oracle, HCL look to clear an ‘easy adoption path’ for mHealth in clinical trials

08-Aug-2019 - Last updated on 08-Aug-2019 at 15:40 GMT

(Image: Getty/metamorworks)

HCL Technologies and Oracle Health Sciences announce a collaboration to “bridge the gap” between the potential of mobile health and the realities of adoption, says EVP.

The technology company, HCL Technologies (HCL), a member of the Oracle Partner Network (OPN), and Oracle Health Sciences, have announced a collaboration to help customers scale digital clinical trials.

Digital transformation is occurring across the clinical trial lifecycle, noted Jonathan Palmer, senior director, product strategy, digital trials, Oracle, who described this change as the basis of the company’s new collaboration with HCL Technologies.

“The industry is emerging from numerous innovative digital trial pilots and global biopharmaceuticals are now looking to implement this innovation at scale,” Palmer told us. “But, navigating the digital transformation journey is not easy, and requires collaboration with domain experts who can help chart the path.”

To address the challenges, Oracle Health Sciences and HCL Technologies are focusing on the organizations “looking to make the move,” said Palmer. Per the collaboration, customers will have access to HCL’s Faster Intelligent Trials (FIT) Solution using Oracle Health Sciences Mobile Health (mHealth) Connector Cloud Service (Oracle mHealth Cloud).

The FIT offering uses Oracle Health Science’s mHealth Connector Cloud Service to aggregate data from various sources, distributing the information to various clinical systems. Additionally, Oracle Health Sciences’ Data Management Workbench and Analytics Cloud will provide analytic capabilities, including machine learning and artificial intelligence.

As Shrikanth Shetty, HCL executive vice president and North America business head for life sciences and health care, told us, the collaboration provides “an easy adoption path for all the benefits of conducting trials digitally.”

“We recognize that the path to adopting mHealth in clinical trials is much more than adoption of piecemeal technology solutions,” Shetty said, adding that HCL helps “bridge the gap between the potential of mHealth and the ground realities of adoption.”

Said Palmer, “We believe the industry, through digital mechanisms, has an enormous opportunity to fundamentally re-invent how clinical research is done, and gain new, deeper insight into human systems.”